FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4366990091> ?p ?o ?g. }

• W4366990091 abstract "Background Recent data on immune evasion of new SARS-CoV-2 variants raise concerns about the efficacy of antibody-based COVID-19 therapies. Therefore, in this study the in-vitro neutralization capacity against SARS-CoV-2 variant B.1 and the Omicron subvariants BA.1, BA.2 and BA.5 of sera from convalescent individuals with and without boost by vaccination was assessed. Methods and findings The study included 313 serum samples from 155 individuals with a history of SARS-CoV-2 infection, divided into subgroups without (n=25) and with SARS-CoV-2 vaccination (n=130). We measured anti-SARS-CoV-2 antibody concentrations by serological assays (anti-SARS-CoV-2-QuantiVac-ELISA (IgG) and Elecsys Anti-SARS-CoV-2 S) and neutralizing titers against B.1, BA.1, BA.2 and BA.5 in a pseudovirus neutralization assay. Sera of the majority of unvaccinated convalescents did not effectively neutralize Omicron sublineages BA.1, BA.2 and BA.5 (51.7%, 24.1% and 51.7%, resp.). In contrast, 99.3% of the sera of superimmunized individuals (vaccinated convalescents) neutralized the Omicron subvariants BA.1 and BA.5 and 99.6% neutralized BA.2. Neutralizing titers against B.1, BA.1, BA.2 and BA.5 were significantly higher in vaccinated compared to unvaccinated convalescents (p&lt;0.0001) with 52.7-, 210.7-, 141.3- and 105.4-fold higher geometric mean of 50% neutralizing titers (NT50) in vaccinated compared to unvaccinated convalescents. 91.4% of the superimmunized individuals showed neutralization of BA.1, 97.2% of BA.2 and 91.5% of BA.5 with a titer ≥ 640. The increase in neutralizing titers was already achieved by one vaccination dose. Neutralizing titers were highest in the first 3 months after the last immunization event. Concentrations of anti-S antibodies in the anti-SARS-CoV-2-QuantiVac-ELISA (IgG) and Elecsys Anti-SARS-CoV-2 S assays predicted neutralization capacity against B.1 and Omicron subvariants BA.1, BA.2 and BA.5. Conclusions These findings confirm substantial immune evasion of the Omicron sublineages, which can be overcome by vaccination of convalescents. This informs strategies for choosing of plasma donors in COVID-19 convalescent plasma programs that shall select specifically vaccinated convalescents with very high titers of anti-S antibodies." @default.
• W4366990091 created "2023-04-27" @default.
• W4366990091 creator A5022594345 @default.
• W4366990091 creator A5025115907 @default.
• W4366990091 creator A5030273113 @default.
• W4366990091 creator A5032138085 @default.
• W4366990091 creator A5035886609 @default.
• W4366990091 creator A5046613528 @default.
• W4366990091 creator A5050122695 @default.
• W4366990091 creator A5060705579 @default.
• W4366990091 creator A5063457498 @default.
• W4366990091 creator A5065858514 @default.
• W4366990091 creator A5068469918 @default.
• W4366990091 creator A5071480424 @default.
• W4366990091 creator A5072303851 @default.
• W4366990091 creator A5075006919 @default.
• W4366990091 creator A5076966548 @default.
• W4366990091 creator A5081633372 @default.
• W4366990091 date "2023-04-25" @default.
• W4366990091 modified "2023-10-11" @default.
• W4366990091 title "SARS-CoV-2 vaccination of convalescents boosts neutralization capacity against Omicron subvariants BA.1, BA.2 and BA.5 and can be predicted by anti-S antibody concentrations in serological assays" @default.
• W4366990091 cites W3032003277 @default.
• W4366990091 cites W3044702419 @default.
• W4366990091 cites W3094755878 @default.
• W4366990091 cites W3114250596 @default.
• W4366990091 cites W3118278606 @default.
• W4366990091 cites W3119294059 @default.
• W4366990091 cites W3133966473 @default.
• W4366990091 cites W3138734145 @default.
• W4366990091 cites W3162160551 @default.
• W4366990091 cites W3163808478 @default.
• W4366990091 cites W3164085336 @default.
• W4366990091 cites W3166210826 @default.
• W4366990091 cites W3167470255 @default.
• W4366990091 cites W3167555428 @default.
• W4366990091 cites W3184640698 @default.
• W4366990091 cites W3196996705 @default.
• W4366990091 cites W3198314694 @default.
• W4366990091 cites W3204742187 @default.
• W4366990091 cites W4200026982 @default.
• W4366990091 cites W4200049484 @default.
• W4366990091 cites W4200391585 @default.
• W4366990091 cites W4200433348 @default.
• W4366990091 cites W4200483499 @default.
• W4366990091 cites W4206693794 @default.
• W4366990091 cites W4210673595 @default.
• W4366990091 cites W4211018598 @default.
• W4366990091 cites W4220665894 @default.
• W4366990091 cites W4220880680 @default.
• W4366990091 cites W4223612665 @default.
• W4366990091 cites W4225463324 @default.
• W4366990091 cites W4226144842 @default.
• W4366990091 cites W4226523125 @default.
• W4366990091 cites W4282935642 @default.
• W4366990091 cites W4283687522 @default.
• W4366990091 cites W4283704819 @default.
• W4366990091 cites W4283831060 @default.
• W4366990091 cites W4285023345 @default.
• W4366990091 cites W4291690734 @default.
• W4366990091 cites W4292662168 @default.
• W4366990091 cites W4307953698 @default.
• W4366990091 cites W4308052871 @default.
• W4366990091 cites W4311359167 @default.
• W4366990091 cites W4313278127 @default.
• W4366990091 cites W4313312703 @default.
• W4366990091 cites W4315753264 @default.
• W4366990091 doi "https://doi.org/10.3389/fimmu.2023.1170759" @default.
• W4366990091 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37180152" @default.
• W4366990091 hasPublicationYear "2023" @default.
• W4366990091 type Work @default.
• W4366990091 citedByCount "1" @default.
• W4366990091 crossrefType "journal-article" @default.
• W4366990091 hasAuthorship W4366990091A5022594345 @default.
• W4366990091 hasAuthorship W4366990091A5025115907 @default.
• W4366990091 hasAuthorship W4366990091A5030273113 @default.
• W4366990091 hasAuthorship W4366990091A5032138085 @default.
• W4366990091 hasAuthorship W4366990091A5035886609 @default.
• W4366990091 hasAuthorship W4366990091A5046613528 @default.
• W4366990091 hasAuthorship W4366990091A5050122695 @default.
• W4366990091 hasAuthorship W4366990091A5060705579 @default.
• W4366990091 hasAuthorship W4366990091A5063457498 @default.
• W4366990091 hasAuthorship W4366990091A5065858514 @default.
• W4366990091 hasAuthorship W4366990091A5068469918 @default.
• W4366990091 hasAuthorship W4366990091A5071480424 @default.
• W4366990091 hasAuthorship W4366990091A5072303851 @default.
• W4366990091 hasAuthorship W4366990091A5075006919 @default.
• W4366990091 hasAuthorship W4366990091A5076966548 @default.
• W4366990091 hasAuthorship W4366990091A5081633372 @default.
• W4366990091 hasBestOaLocation W43669900911 @default.
• W4366990091 hasConcept C14086860 @default.
• W4366990091 hasConcept C159047783 @default.
• W4366990091 hasConcept C159654299 @default.
• W4366990091 hasConcept C203014093 @default.
• W4366990091 hasConcept C22070199 @default.
• W4366990091 hasConcept C22889606 @default.
• W4366990091 hasConcept C2779261636 @default.
• W4366990091 hasConcept C32611913 @default.
• W4366990091 hasConcept C45189115 @default.
• W4366990091 hasConcept C71924100 @default.
• W4366990091 hasConceptScore W4366990091C14086860 @default.

• next